Katherine High, M.D.

Katherine A. High is Emeritus Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. A renowned hematologist, her research group pioneered safe and effective clinical translation of genetic therapies for inherited disorders. Her studies have led to long-term correction of disease in men with hemophilia B, and long-term improvements in vision in children and adults with a rare form of hereditary blindness. She is currently co-founder, President and Chief Scientific Officer of Spark Therapeutics, Inc., a company focused on the development of gene therapy. Dr. High served on the NHLBI Hematology I study section (1994-98), the NHLBI Program Project Parent Review Committee (2001-2004), and the NHLBI Advisory Council (2005-2008), as well as the NHLBI Gene Therapy Resource Program Steering Committee (2008-2014). Currently she serves on the NHLBI Sickle Cell Disease Advisory Committee.

Read more about Dr. High.